AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company will present a poster highlighting the preclinical activity of epetraborole against M. abscessus on Thursday, May 29, 2025 at the Nontuberculous Mycobacteria Conference to be held May 27-30, 2025 at Colorado State University. It is estimated that M. abscessus affects approximately 50,000 patients in the U.S., Japan and Europe.
Details of the poster presentation are as follows:
Abstract title: Epetraborole, a Potential Oral Agent for Mycobacterium abscessus Lung Disease
Date and Time:
Poster/Abstract number: 74
Presenting Author: MRK Alley, Ph.D.
A copy of the poster will be available on the AN2 Therapeutics website at the following link simultaneously with the poster session Development Pipeline | AN2 Therapeutics.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. AN2 has a pipeline of boron-based compounds in development for Chagas disease, melioidosis, and NTM lung disease caused by M. abscessus, along with early-stage programs focused on targets in infectious diseases and oncology. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes. For more information, please visit our website at www.an2therapeutics.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
24 minutes ago
- Business Wire
Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025
BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow (United Kingdom) June 13-16. The company will present 25 posters and host two scientific symposia during which six world-leading experts will share their insight on respiratory and food allergy: 'Breath of change: redefining respiratory allergy care with remission in sight': with environmental change impacting respiratory allergies, a new approach to disease management is necessary. Clinical remission is emerging as a relevant treatment goal for Type 2 allergies and allergen immunotherapy (AIT) has the potential to cater to this approach. ' Myth busting in peanut allergy: separating fact from fiction ': misconceptions about food allergy management may influence treatment decisions, thus underscoring the vital role of patient-clinician communication. ' We are enthusiastic to share how Stallergenes Greer is bolstering its impact in the field of respiratory and food allergy. Our research findings highlighted at the symposia, as well as through scientific posters and presentations, reflect our determination to deliver innovative allergen immunotherapy solutions that offer sustained benefits for patients worldwide,' stated Dr Elena Rizova, Chief Medical Officer, Stallergenes Greer. ' Our portfolio offers a broad range of proven treatment solutions designed to provide long-lasting relief for patients with allergies across a spectrum of conditions ranging from allergic rhinitis and asthma to food allergy.' The presentation of the posters will showcase Stallergenes Greer's latest research efforts and reaffirm its commitment to advancing personalised allergy care for the benefit of patients and healthcare professionals. Topics include patient benefits with AIT and its potential for clinical remission, new data from the recent real-world study VORAN on 300 IR House Dust Mite (HDM) SLIT tablet, PDAH (defatted powder of Arachis Hypogaea L., semen [peanut]) allergen consistency compared to supermarket peanut products, and prevention of food-induced anaphylaxis in children, including toddlers. SYMPOSIA AND POSTERS COMPANY SPONSORED SYMPOSIUM (June 13, 13:30–14:30 – Room: Meeting Academy M1) "Breath of change: redefining respiratory allergy care with remission in sight" Chair: Prof. Adnan Custovic, United Kingdom - 'Climate, pollution, and the escalating allergy burden: time for a treatment paradigm shift' Speaker: Prof. Guillaume Lezmi, France - 'From symptom control to disease remission: a new vision for allergic asthma' Speaker: Prof. Oliver Pfaar, Germany - 'Allergen immunotherapy: unlocking sustainable relief for allergic rhinitis' Speaker: Prof. Randolph Brehler, Germany COMPANY SPONSORED SYMPOSIUM (June 14, 14:30–15:00 – Room: Boisdale) ' Myth busting in peanut allergy: separating fact from fiction ' Speakers: Dr Aikaterini Anagnostou, United States of America, and Dr Pablo Rodríguez del Río, Spain POSTERS Among the topics covered by the 25 posters, specific findings will be presented and discussed in depth: Recent findings highlight the potential of Stallergenes Greer immunotherapies to provide sustained symptom relief and reduce reliance on corticosteroids even after treatment cessation, aligning with the concept of clinical remission on and off treatment. Evidence from VORAN, the first European real-world data generation study with 300 IR HDM SLIT tablet, supports the safety profile and effectiveness of this treatment in HDM-induced allergic rhinitis with or without controlled asthma in more than 700 adults and adolescents, with over 80% having improved their symptoms and sleep and almost 2/3 stopping nasal corticosteroid use. These findings are further supported by the PRACTIS study, where the benefits of SLIT-liquid met expectations in approximately 90% of patients with allergic rhino conjunctivitis and/or asthma. Furthermore, Stallergenes Greer recently conducted studies showing that its peanut allergy treatment, PDAH, is consistent and offers a positive risk-benefit ratio. Unlike common peanut products found in supermarkets, which can vary in protein and allergen levels, PDAH shows consistency across batches. The research also points to an opportunity to help children from 1 year, when their immune systems may be more adaptable. In clinical studies, the treatment helped reduce the risk of accidental allergic reactions and showed a solid safety record, especially in toddlers. ABOUT THE EAACI CONGRESS The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 16,000 members from 125 countries and over 50 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy. Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. For more information, visit
Yahoo
25 minutes ago
- Yahoo
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated approach targeting HBG1/2 promoters to upregulate fetal hemoglobin (HbF) is in pre-clinical development as a potential transformative in vivo gene editing medicine for the treatment of sickle cell disease and beta thalassemia. The Company reported these data in a presentation available today and will detail the data in a poster session on Saturday, June 14th 6:30 - 7:30 p.m. CEST (12:30 – 1:30 p.m. EDT) at the European Hematology Association (EHA) 2025 Congress in Milan, Italy. In this study, the Company's proprietary tLNP formulation delivered HBG1/2 promoter editing cargo to HSCs in NHPs. Latest data from this ongoing NHP study showed that at five months a single intravenous administration of Editas' tLNP resulted in mean on-target editing levels in the HBG1/2 promoter region of 58% in HSCs: well exceeding the predicted editing threshold of ≥25% required for therapeutic benefit. In addition to achieving therapeutically relevant editing levels, the biodistribution data in NHPs with Editas' tLNP continue to show significant de-targeting of the liver in contrast to standard LNPs. 'These data from our in vivo HSC program confirm our ability to achieve high efficiency delivery, therapeutically relevant editing levels and favorable biodistribution in NHPs. These data validate the further development of Editas' proprietary HSC-tLNP for editing of the HBG1/2 promoters for the treatment of sickle cell disease and beta thalassemia,' said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. Editas Medicine's in vivo HSC program targets HBG1/2 promoters to mimic naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH) and utilizes proprietary AsCas12a to edit with high efficiency and minimize off-target editing. Editing the HBG1/2 promoters with AsCas12a with the investigational medicine reni-cel led to robust increases in HbF and total hemoglobin (Hb) in clinical trials. The presentation details are listed below. Abstracts can be accessed on the EHA website, and the presentation will be posted on the Editas Medicine website during the conference. Poster Presentation Details: Title: Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for β-hemoglobinopathies Date/Time: Saturday, June 14, 2025, 6:30 - 7:30 p.m. CEST/ 12:30 – 1:30 p.m. EDT Location: Allianz MiCo, Milano Convention Centre Session: Poster Session 2 About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit CONTACT: Media and Investor Contacts: media@ ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
25 minutes ago
- CNBC
Trade tensions aren't stopping Chinese companies from pushing into the U.S.
BEIJING — Chinese companies are so intent on global expansion that even the biggest stock offering to date on Shanghai's tech-heavy STAR board counts the U.S. as one of its biggest markets, on par with China. Shenzhen-based camera company Insta360, a rival to GoPro, raised 1.938 billion yuan ($270 million) in a Shanghai listing Wednesday under the name Arashi Vision. Shares soared by 274%, giving the company a market value of 71 billion yuan ($9.88 billion). The United States, Europe and mainland China each accounted for just over 23% of revenue last year, according to Insta360, whose 360-degree cameras officially started Apple Store sales in 2018. The company sells a variety of cameras — priced at several hundred dollars — coupled with video-editing software. Co-founder Max Richter said in an interview Tuesday that he expects U.S. demand to remain strong and dismissed concerns about geopolitical risks. "We are staying ahead just by investing into user-centric research and development, and monitoring market trends that ultimately meet the consumer['s] needs," he told CNBC ahead of the STAR board listing. China launched the Shanghai STAR Market in July 2019 just months after Chinese President Xi Jinping announced plans for the board. The Nasdaq-style tech board was established to support high-growth tech companies while raising requirements for the investor base to limit speculative activity. In 2019, only 12% of companies on the STAR board said at least half of their revenue came from outside China, according to CNBC analysis of data accessed via Wind Information. In 2024, with hundreds more companies listed, that share had climbed to more than 14%, the data showed. "We are just seeing the tip of the iceberg. More and more capable Chinese firms are going global," said King Leung, global head of financial services, fintech and sustainability at InvestHK. Leung pointed to the growing global business of Chinese companies such as battery giant CATL, which listed in Hong Kong last month. "There are a lot of more tier-two and tier-three companies that are equally capable," he said. InvestHK is a Hong Kong government department that promotes investment in the region. It has organized trips to help connect mainland Chinese businesses with overseas opportunities, including one to the Middle East last month. Roborock, a robotic vacuum cleaner company also listed on the STAR board, announced this month it plans to list in Hong Kong. More than half of the company's revenue last year came from overseas markets. At the Consumer Electronics Show in Las Vegas this year, Roborock showed off a vacuum with a robotic arm for automatically removing obstacles while cleaning floors. The device was subsequently launched in the U.S. for $2,600. Other consumer-focused Chinese companies also remain unfazed by heighted tensions between China and the U.S. In November, Chinese home appliance company Hisense said it aimed to become the top seller of television sets in the U.S. in two years. And last month, China-based Bc Babycare announced its official expansion into the U.S. and touted its global supply chain as a way to offset tariff risks. Chinese companies have been pushing overseas in the last several years, partly because growth at home has slowed. Consumer demand has remained lackluster since the Covid-19 pandemic. But the expansion trend is now evolving into a third stage in which the businesses look to build international brands on their own with offices in different regions hiring local employees, said Charlie Chen, managing director and head of Asia research at China Renaissance Securities. He said that's a change from the earliest years when Chinese companies primarily manufactured products for foreign brands to sell, and a subsequent phase in which Chinese companies had joint ventures with foreign companies. Insta360 primarily manufactures out of Shenzhen, but has offices in Berlin, Tokyo and Los Angeles, Richter said. He said the Los Angeles office focuses on services and marketing — the company held its first big offline product launch in New York's Grand Central Terminal in April. Chen also expects the next phase of Chinese companies going global will sell different kinds of products. He pointed out that those that had gone global primarily sold home appliances and electronics, but are now likely to expand significantly into toys. Already, Beijing-based Pop Mart has become a global toy player, with its Labubu figurine series gaining popularity worldwide. Pop Mart's total sales, primarily domestic, were 4.49 billion yuan in 2021. In 2024, overseas sales alone surpassed that to hit 5.1 billion yuan, up 373% from a year ago, while mainland China sales climbed to 7.97 billion yuan. "It established another Pop Mart versus domestic sales in 2021," said Chris Gao, head of China discretionary consumer at CLSA. The Hong Kong-listed retailer doesn't publicly share much about its global store expansion plans or existing locations, but an independent blogger compiled a list of at least 17 U.S. store locations as of mid-May, most of which opened in the last two years. The toy company has been "very good" at developing or acquiring the rights to characters, Gao said. She expects its global growth to continue as Pop Mart plans to open more stores worldwide, and as consumers turn more to such character-driven products during times of stress and macroeconomic uncertainty.
